OS Therapies Incorporated (OSTX)
XASE:OSTX
Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.15 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)693.17K
Market Cap
$75.71M
Enterprise Value$520.70M
Total Cash (Recent Filing)$917.55M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Aug 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding44,538,105
10 Day Avg. Volume687,415
30 Day Avg. Volume693,174
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.44K
Enterprise Value/Ebitda-15.00
Forecast
1Y Price Target
$9.50Price Target Upside559.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$2.67M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressA formal EMA rolling review with aligned three-year overall survival endpoints, selection for the EMA Raw Data Pilot and UK ATMP status materially de-risks the regulatory pathway. This durable clarity supports coordinated global Phase 3 planning, reimbursement discussions, and increases the probability of conditional approvals that underpin long-term commercial opportunity.
Near-Term Funding RunwayMultiple financings plus expected non-dilutive VAT refunds and R&D tax credits extend runway into 2027, providing capital to complete planned regulatory submissions and a confirmatory Phase 3 start. This reduces short-term financing pressure and allows focus on clinical execution and milestone delivery, improving odds of surviving to value-creating inflection points.
Focused Pipeline & PlatformA concentrated, biomarker-driven pipeline (OST-HER2 plus OST-504/OST-503) and intent to pursue ADC and IO approaches create a scalable platform in immuno-oncology. Platform focus and biomarker alignment support durable competitive differentiation, clearer patient selection, and potential to expand indications beyond osteosarcoma if lead-program validation succeeds.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow across periods shows the company is not self-financing development. Worsening burn in recent periods increases dependence on external capital, making clinical progress contingent on successful financings and elevating long-term dilution and execution risk if milestones slip or funding gaps appear.
Elevated Leverage And LossesMaterial increase in debt at a pre-revenue, clinical-stage company and sharply negative ROE signal weaker financial resilience. High leverage constrains operating flexibility, increases financing costs and covenant risk, and amplifies downside if clinical or regulatory setbacks delay revenue realization or require additional capital.
Dilution & Financing ConstraintsReliance on convertible notes, registered direct offerings, placement-agent warrants and a resale shelf creates near-term dilution risk and complex capital structure. Debt conversion terms, warrants and covenants that limit additional financings reduce strategic flexibility and can pressure existing shareholders' economic ownership over the medium term.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $75.71M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Aug 13, 2026 which is in 58 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on May 18, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.16.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 44,538,105 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (559.72% Upside)
$9.50 (559.72% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.60%
12-Months-Change
Fundamentals
Return on Equity
3214.88%
Trailing 12-Months
Asset Growth
71.75%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HER2, a readily available immunotherapy developed for osteosarcoma patients, alongside OST-tunable drug conjugate (OST-tADC). This innovative antibody-drug conjugate technology leverages a modular 'plug-and-play' platform equipped with customizable, pH-sensitive silicone linkers. Established in 2018, OS Therapies Incorporated is headquartered in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$9.50
▲(559.72% Upside)
Technical Analysis
Ownership Overview
8.31% Insiders
1.54% Mutual Funds
1.69% Other Institutional Investors
87.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---